Skip to main content

Azenta Value Stock - Dividend - Research Selection

Brooks automation

ISIN: US1143401024 , WKN: 257275

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!

How our site works ...

✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month 
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Brooks Automation, Inc. provides automation and cryogenic solutions for various applications and markets. It operates in two segments, Brooks Semiconductor Solutions Group and Brooks Life Science Systems. The Brooks Semiconductor Solutions Group segment offers critical automated transport, vacuum, and contamination controls solutions and services. Its products include atmospheric and vacuum robots, robotic modules, and tool automation systems that offer precision handling and clean wafer environments; automated cleaning and inspection systems for wafer carriers, as well as reticle pod cleaners and stockers; and vacuum pumping and thermal management solutions for critical process vacuum applications. This segment also offers repair, diagnostic, and installation services, as well as spare parts and productivity enhancement upgrade services. The Brooks Life Science Systems segment provides automated cold storage systems; consumables, including various formats of racks, tubes, caps, plates, and foils; and instruments used for labeling, bar coding, capping, decapping, auditing, sealing, peeling, and piercing tubes and plates. It also provides sample management services, such as on-site and off-site sample storage, cold chain logistics, sample relocation, bio-processing, disaster recovery, and business continuity, as well as project management and consulting. In addition, this segment offers sample intelligence software solutions and customer technology integration; and laboratory work flow scheduling for life science tools and instrument work cells, sample inventory and logistics, environmental and temperature monitoring, and clinical trial and consent management, as well as planning, data management, virtualization, and visualization services. The company serves semiconductor capital equipment and sample management markets for life sciences in approximately 50 countries. Brooks Automation, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Q2 Earnings Review: Drug Development Inputs & Services Stocks Led by Azenta (NASDAQ:AZTA)

2026-09-14
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including Azenta (NASDAQ:AZTA) and its peers.

Needham Reiterates Buy on Azenta, Maintains $37 Price Target

2026-09-14
Needham analyst David Saxon reiterates Azenta (NASDAQ:AZTA) with a Buy and maintains $37 price target.

Azenta Receives Full Repayment of $35 Million Vendor Loan Related to Sale of B Medical Systems

2026-09-04
Azenta, Inc. (Nasdaq: AZTA) today announced that it has received repayment in full, prior to maturity, of the $35 million secured vendor loan extended in connection with the previously announced sale of B Medical Systems S.à r.l. to Thelema S.à r.l.

3 Healthcare Stocks We Keep Off Our Radar

2026-09-01
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 22.1% over the past six months while the S&P 500 was up 12.1%.

Stocks making big moves yesterday: Funko, Hims & Hers Health, Azenta, Strategy, and RUM Group

2026-08-25
Check out the companies making headlines yesterday:

Why Azenta (AZTA) Stock Is Down Today

2026-08-24
Shares of life sciences company Azenta (NASDAQ:AZTA) fell 9.1% in the afternoon session after the company announced, in a regulatory filing, that President and CEO John Marotta resigned from his executive roles and board seat, with current director Dr. Martin Madaus appointed as interim President and CEO.

Crude Oil Down 3%; XPeng Shares Fall After Q2 Results

2026-08-24
US stocks traded mixed with the Dow Jones index gaining over 150 points. Consumer staples shares jumped while information technology stocks fell. XPeng Inc shares fell 7% due to wider than expected loss and lower revenue outlook.

AZENTA ANNOUNCES LEADERSHIP TRANSITION

2026-08-24
Azenta, Inc. (Nasdaq: AZTA) ("Azenta" or "the Company") today announced that current member of the Board of Directors (the "Board") Dr. Martin Madaus has been appointed interim President and CEO, and that John Marotta has resigned as an executive officer and director of the Company.

Azenta Appoints Martin Madaus Interim President, CEO; Co. Reiterates Q4 Revenue Outlook

2026-08-24
Azenta, Inc. (Nasdaq: AZTA) ("Azenta" or "the Company") today announced that current member of the Board of Directors (the "Board") Dr. Martin Madaus has been appointed interim President and CEO,

1 Momentum Stock for Long-Term Investors and 2 We Find Risky

2026-08-19
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.